{"id":3666,"date":"2022-10-27T17:38:12","date_gmt":"2022-10-27T15:38:12","guid":{"rendered":"https:\/\/www.biopole-clermont.com\/?post_type=communiques&#038;p=3666"},"modified":"2022-11-10T17:38:50","modified_gmt":"2022-11-10T16:38:50","slug":"valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th","status":"publish","type":"communiques","link":"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/","title":{"rendered":"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)."},"template":"","type_de_communiques_de_presse":[],"entreprise":[303],"zentreprise":[],"class_list":["post-3666","communiques","type-communiques","status-publish","hentry","entreprise-valbiotis-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.2 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). - Biop\u00f4le Clermont-Limagne<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). - Biop\u00f4le Clermont-Limagne\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/\" \/>\n<meta property=\"og:site_name\" content=\"Biop\u00f4le Clermont-Limagne\" \/>\n<meta property=\"article:modified_time\" content=\"2022-11-10T16:38:50+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/\",\"url\":\"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/\",\"name\":\"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). - Biop\u00f4le Clermont-Limagne\",\"isPartOf\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#website\"},\"datePublished\":\"2022-10-27T15:38:12+00:00\",\"dateModified\":\"2022-11-10T16:38:50+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/www.biopole-clermont.com\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Communiqu\u00e9s de presse\",\"item\":\"https:\/\/www.biopole-clermont.com\/en\/communiques\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD).\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.biopole-clermont.com\/en\/#website\",\"url\":\"https:\/\/www.biopole-clermont.com\/en\/\",\"name\":\"Biop\u00f4le Clermont-Limagne\",\"description\":\"Technopole des sciences du vivant\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.biopole-clermont.com\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). - Biop\u00f4le Clermont-Limagne","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/","og_locale":"en_US","og_type":"article","og_title":"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). - Biop\u00f4le Clermont-Limagne","og_url":"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/","og_site_name":"Biop\u00f4le Clermont-Limagne","article_modified_time":"2022-11-10T16:38:50+00:00","twitter_card":"summary_large_image","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/","url":"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/","name":"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD). - Biop\u00f4le Clermont-Limagne","isPartOf":{"@id":"https:\/\/www.biopole-clermont.com\/en\/#website"},"datePublished":"2022-10-27T15:38:12+00:00","dateModified":"2022-11-10T16:38:50+00:00","breadcrumb":{"@id":"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/www.biopole-clermont.com\/en\/communiques\/valbiotis-will-present-significant-preclinical-results-for-its-active-substance-totum448-against-fatty-liver-diseases-nafl-and-nash-at-the-annual-meeting-of-the-american-association-for-th\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/www.biopole-clermont.com\/en\/"},{"@type":"ListItem","position":2,"name":"Communiqu\u00e9s de presse","item":"https:\/\/www.biopole-clermont.com\/en\/communiques\/"},{"@type":"ListItem","position":3,"name":"Valbiotis will present significant preclinical results for its active substance TOTUM\u2022448 against fatty liver diseases (NAFL and NASH), at the annual meeting of the American Association for the Study of Liver Diseases (AASLD)."}]},{"@type":"WebSite","@id":"https:\/\/www.biopole-clermont.com\/en\/#website","url":"https:\/\/www.biopole-clermont.com\/en\/","name":"Biop\u00f4le Clermont-Limagne","description":"Technopole des sciences du vivant","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.biopole-clermont.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"_links":{"self":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/communiques\/3666","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/communiques"}],"about":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/types\/communiques"}],"version-history":[{"count":1,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/communiques\/3666\/revisions"}],"predecessor-version":[{"id":3667,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/communiques\/3666\/revisions\/3667"}],"wp:attachment":[{"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/media?parent=3666"}],"wp:term":[{"taxonomy":"type_de_communiques_de_presse","embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/type_de_communiques_de_presse?post=3666"},{"taxonomy":"entreprise","embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/entreprise?post=3666"},{"taxonomy":"zentreprise","embeddable":true,"href":"https:\/\/www.biopole-clermont.com\/en\/wp-json\/wp\/v2\/zentreprise?post=3666"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}